Smoking-related diseases kill more Americans than alcohol, illegal drugs, murder and suicide combined. The passage of the Family Smoking Prevention and Tobacco Control Act of 2009 gave the FDA authority to regulate "modified risk tobacco products" (MRTPs), tobacco products that are either designed or advertised to reduce harm or the risk of tobacco-related disease. MRTPs must submit to the FDA scientific evidence to demonstrate the product has the potential to reduce tobacco related harms as compared to conventional tobacco products. The IOM identifies minimum standards for scientific studies that an applicant would need to complete to obtain an order to market the product from the FDA.

"The title of our hearing, 'Can Tobacco Cure Smoking?' at first blush seems counterintuitive. However, there is an increasing amount of research suggesting that some tobacco products are less harmful than others. For those smokers who can't seem to quit smoking, switching to a less hazardous product could save lives. Today we will hear from a diverse group of experts espousing a range of opinions on issues of tobacco harm reduction. We worked closely with the minority to insure a fair and balance panel of witnesses that can speak to the science of this issue"--Page 2

This eighth report of the Study Group addresses electronic nicotine delivery system (ENDS), electronic non-nicotine delivery system (ENNDS) and heated tobacco product (HTPs); however, it does not cover all aspects of these products, because many of the papers were written to meet the request of COP8, which was to review understanding on novel and emerging tobacco products (FCTC/COP8). Continued research is necessary on these products; the Study Group will cover other products of interest (including traditional products, such as waterpipes, cigarettes and smokeless tobacco) in its next report, guided by countries’ regulatory requirements and pertinent issues in tobacco product regulation. This will ensure continued, timely technical support to all countries and address all products, recognizing that their availability depends on the jurisdiction.

This report presents the conclusions reached and recommendations made by the members of the WHO Study Group on Tobacco Product Regulation (TobReg) at its seventh meeting in December 2013 during which it reviewed background papers specially commissioned for the meeting and which dealt respectively with the following four themes: Novel tobacco products including potential reduced exposure products ; Smokeless tobacco products: research needs and regulatory recommendations ; Reduced ignition propensity cigarettes: research needs and regulatory recommendations and Non-exhaustive priority list of toxic contents and emissions of tobacco products. The Study Group's recommendations in relation to each theme are set out at the end of the section dealing with that theme; its overall recommendations are summarized in Chapter 6.

Volume 67 in the internationally acclaimed Advances in Clinical Chemistry contains chapters authored by world renowned clinical laboratory scientists, physicians and research scientists. The serial provides the latest and most up-to-date technologies related to the field of Clinical Chemistry and is the benchmark for novel analytical approaches in the clinical laboratory. - Expertise of international contributors - Latest cutting-edge technologies - Comprehensive in scope

Despite overwhelming evidence of tobacco's harmful effects and pressure from anti-smoking advocates, current surveys show that about one-quarter of all adults in the United States are smokers. This audience is the target for a wave of tobacco products and pharmaceuticals that claim to preserve tobacco pleasure while reducing its toxic effects. Clearing the Smoke addresses the problems in evaluating whether such products actually do reduce the health risks of tobacco use. Within the context of regulating such products, the committee explores key questions: Does the use of such products decrease exposure to harmful substances in tobacco? Is decreased exposure associated with decreased harm to health? Are there surrogate indicators of harm that could be measured quickly enough for regulation of these products? What are the public health implications? This book looks at the types of products that could reduce harm and reviews the available evidence for their impact on various forms of cancer and other major ailments. It also recommends approaches to governing these products and tracking their public health effects. With an attitude of healthy skepticism, Clearing the Smoke will be important to health policy makers, public health officials, medical practitioners, manufacturers and marketers of "reduced-harm" tobacco products, and anyone trying to sort through product claims.

The nation has made tremendous progress in reducing tobacco use during the past 40 years. Despite extensive knowledge about successful interventions, however, approximately one-quarter of American adults still smoke. Tobacco-related illnesses and death place a huge burden on our society. Ending the Tobacco Problem generates a blueprint for the nation in the struggle to reduce tobacco use. The report reviews effective prevention and treatment interventions and considers a set of new tobacco control policies for adoption by federal and state governments. Carefully constructed with two distinct parts, the book first provides background information on the history and nature of tobacco use, developing the context for the policy blueprint proposed in the second half of the report. The report documents the extraordinary growth of tobacco use during the first half of the 20th century as well as its subsequent reversal in the mid-1960s (in the wake of findings from the Surgeon General). It also reviews the addictive properties of nicotine, delving into the factors that make it so difficult for people to quit and examines recent trends in tobacco use. In addition, an overview of the development of governmental and nongovernmental tobacco control efforts is provided. After reviewing the ethical grounding of tobacco control, the second half of the book sets forth to present a blueprint for ending the tobacco problem. The book offers broad-reaching recommendations targeting federal, state, local, nonprofit and for-profit entities. This book also identifies the benefits to society when fully implementing effective tobacco control interventions and policies.